Leucine zipper-based sorting system enables generation of multi-functional CAR T cells
Scott E. JamesiD, Sophia CheniD, Brandon D. NgiD, Jacob S. FischmaniD, Lorenz JahniD, Alexander P. Boardman, Adhithi RajagopalaniD, Harold Kunal EliasiD, Alyssa MassaiD, Dylan ManueleiD, Katherine B. NicholsiD, Amina LazrakiD, Nicole MynYi LeeiD, Teng FeiiD, Susan DeWolfiD, Jonathan U. PelediD, Santosha Adipudi VardhanaiD, Christopher Austin KlebanoffiD, Marcel R.M. van den BrinkiD
Abstract
Resistance to chimeric antigen receptor (CAR) T cell therapy develops through multiple mechanisms including antigen-loss escape and tumor-induced immune suppression. Expression of multiple CARs may overcome multi-antigen-loss escape. Similarly, expression of switch receptors that convert inhibitory immune checkpoint signals into positive costimulatory signals may enhance CAR T cell activity in the tumor microenvironment. Engineering multiple features into one cell product, however, is limited by transgene packaging constraints of current vector systems. Here, we describe a leucine zipper-based cell sorting methodology that enables selective single-step immunomagnetic purification of cells co-transduced with two vectors, designed to potentially double the number of incorporated transgenes. This "Zip-sorting" system facilitated generation of T cells simultaneously expressing up to four CARs and co-expressing up to three switch receptors. These multi-CAR multi-Switch receptor arrays enabled T cells to eliminate antigenically heterogeneous syngeneic leukemia populations co-expressing multiple inhibitory ligands. Zip-sorted multi-CAR multi-Switch receptor T cells represent a potent therapeutic strategy to overcome multiple mechanisms of CAR T cell resistance.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Microfluidic T-Chip enables one-step clinical-scale T-cell purification from blood products for CAR T-cell manufacturing
Maheen Rana, Sophia E. Nigrovic, … Avanish Mishra·bioRxiv·Jul 31, 2026
- Comprehensive genome editing confers "off-the-shelf" CAR-T cells superior efficacy against solid tumors
R. Murray, N. R. R. Navarrete, … S. Hatfield·bioRxiv·Aug 3, 2023
- Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance
S. Levesque, G. Carleton, … Y. Doyon·bioRxiv·Sep 14, 2023
- Quantum CART (qCART), a piggyBac-based system for development and production of virus-free multiplex CAR-T cell therapy
Y.-C. Chen, W.-K. Hua, … S. C.-Y. Wu·bioRxiv·May 3, 2022
- Generation of anti-tumor chimeric antigen receptors incorporating T cell signaling motifs
L. Balagopalan, T. Moreno, … L. E. Samelson·bioRxiv·Dec 25, 2022
- Engineering clinically-approved drug gated CAR circuits
Hui-Shan Li, Nicole M. L. Wong, … Wilson W. Wong·Cancer CellPeer-reviewed·Sep 8, 2022